Vivion Investments S.à r.l. (“Vivion“) announces today the establishment of a EUR1,000,000,000 Euro Medium Term Note Programme (the “EMTN Programme“).
The EMTN Programme allows Vivion to opportunistically access favourable bond market windows in a timely manner, optimise its long term cost of funding and provides flexibility to take advantage of potential acquisition opportunities. Vivion does not immediately offer new notes and is focused to maintain a prudent and conservative financial policy. Notes issued under the EMTN Programme will rank pari passu with the Vivion’s outstanding senior notes.
Aside the issuance of new unsecured debt, Vivion has several other elements to further support is financing strategy, including a cash position of EUR 722 million as of 30 June 2022, along with EUR 3.1 billion of unencumbered assets that it can use for refinancing of existing debt or fund new acquisitions.
The base listing particulars for the EMTN Programme is dated November 11, 2022 and has been approved by Euronext Dublin. Application will be made to Euronext Dublin for any notes issued under the EMTN Programme to be admitted to its official list and to trading on the Global Exchange Market, which is the exchange-regulated market of Euronext Dublin.
Important Notice
This release is for informational purposes only and shall not constitute a prospectus or an offer to sell or the solicitation of an offer to buy securities in the United States or any other jurisdiction.
Forward-Looking Statements
This release contains “forward-looking statements”, as the phrase is defined in Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. The words “expect,” “will,” and similar words are intended to identify estimates and forward-looking statements. Forward-looking statements are not historical facts. Forward-looking statements involve risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, actual results could differ materially from those expressed or implied by such forward-looking statements or assumptions. Certain other factors that could cause actual results to differ materially from those discussed in any forward-looking statements include the risk factors described in the Base Listing Particulars. The forward-looking statements included in this release are made only as of the date hereof, and Vivion disclaims any obligation to update them or to announce publicly any revision to any of the forward-looking statements contained in this release, or to make corrections to reflect future events or developments.

